Detail akcie Macrogenics online

Business Summary: MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Financial Summary: BRIEF: For the six months ended 30 June 2025, MacroGenics Inc revenues increased 78% to $35.4M. Net loss decreased 28% to $77.3M. Revenues reflect Contract manufacturing increase from $5.2M to $21.5M, Revenue From Collaborative Agreements increase from $3.5M to $13.9M. Lower net loss reflects Research&development-Bal Val decrease of 18% to $75.2M (expense), General and administrative - Balancing decrease of 25% to $17.3M (expense).